Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Citizens Jmp

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by investment analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating in a report issued on Thursday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on VIGL. Wedbush cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and decreased their price objective for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. Jefferies Financial Group downgraded Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright lowered their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Citigroup lowered Vigil Neuroscience to a "market perform" rating in a research report on Thursday, May 22nd. Finally, Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the company a "neutral" rating in a report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $10.80.

Vigil Neuroscience Stock Up 0.1%

NASDAQ VIGL traded up $0.01 during trading hours on Thursday, hitting $7.89. 586,286 shares of the company were exchanged, compared to its average volume of 642,602. The firm has a market cap of $368.01 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The company has a 50 day moving average of $2.43 and a two-hundred day moving average of $2.35. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, equities research analysts predict that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC boosted its holdings in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after acquiring an additional 8,358 shares during the period. Jane Street Group LLC purchased a new stake in Vigil Neuroscience in the 4th quarter valued at $83,000. Barclays PLC boosted its stake in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after purchasing an additional 19,436 shares during the period. Northern Trust Corp boosted its stake in Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after purchasing an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP grew its position in Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after purchasing an additional 49,000 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.